Tag:
Phase II
Latest Headlines
Latest Headlines
Ph2 Roche study delivers promising long-term ocrelizumab data on MS
Roche posted positive long-term Phase II numbers for its MS drug ocrelizumab, winning kudos for success outside of the cancer field. But analysts were quick to deduct points on the promising
UPDATED: Sangamo scuttles lead drug program after it fails PhIIb
Just two weeks after impressing analysts with some intriguing initial efficacy data on a new approach to treating HIV, Sangamo BioSciences ($SGMO) today pulled the plug on its lead therapy after the
AstraZeneca flunks Ph2 lung cancer trial with drug from Array BioPharma
Array BioPharma ($ARRY) delivered some bad news this morning about one of its experimental cancer drugs. AstraZeneca--which has licensed Array's the drug, selumetinib--came up short in in a mid-stage
Roche HDL drug dalcetrapib clears a crucial safety test
Roche appears to have navigated safe passage around a couple of the clinical landmines awaiting any mid-stage HDL study, noting that data from their Phase II trial of dalcetrapib demonstrated that
Peregrine shares spike on Ph2 cancer data
Shares of Peregrine Pharmaceuticals ($PPHM) spiked 20% this morning after the company reported that advanced and metastatic breast cancer patients taking a combination of bavituximab and docetaxel
Roche preps vismodegib app with "profound" efficacy data
Armed with positive data from a pivotal Phase II trial, Lexington, MA-based Curis is waiting for its partner Roche to begin its long-awaited pitch to gain FDA approval for a new treatment for
Alder lands $15M milestone from blockbuster BMS antibody deal
Alder Biopharmaceuticals says that it will pocket a $15 million milestone payment from Bristol-Myers Squibb now that the pharma company has launched a Phase IIb study of ALD518/BMS-945429, an IL-6
Roche preps vismodegib app after Ph2 skin cancer success
Roche and Genentech have posted a fresh set of promising mid-stage data on vismodegib, a cancer drug it's collaborating on with Lexington, MA-based Curis. In what investigators describe as a pivotal
Exelixis shares slide as CEO cheers a mid-stage prostate cancer success
Not long after Mike Morrissey took the helm at Exelixis ($EXEL) in the summer of 2010 he decided to restructure and go all in on cabozantinib, the biotech's promising cancer drug that had already
UPDATED: ASCO roundup: Fresh progress of Merck, Pfizer cancer drugs
The burst of cancer drug news out of ASCO has spotlighted significant advances on a host of new drug programs, with Merck and Pfizer both benefiting from the limelight. (You can find fresh data on
- « first
- ‹ previous
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- next ›
- last »
